Penumbra (PEN) Current Deferred Revenue (2022)
Penumbra's (PEN) quarterly Current Deferred Revenue came in at $9.6 million in Q2 2022, up 28.0% on a QoQ basis from $7.5 million in Q1 2022.
Penumbra (PEN) Current Deferred Revenue (2022) Analysis & Trends
Penumbra (PEN) has 1 years of Current Deferred Revenue data on file, last reported at $9.6 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 9.60 Mn |
| Mar 31, 2022 | 7.50 Mn |